Home - Products - Others - Other Targets - Caspase 1 Substrate 1m (ICE), fluorogenic

Caspase 1 Substrate 1m (ICE), fluorogenic

CAS No. ———

Caspase 1 Substrate 1m (ICE), fluorogenic( ——— )

Catalog No. M41683 CAS No. ———

Caspase 1 Substrate 1m (ICE), fluorogenic; Ac-YEVD-AMC

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Caspase 1 Substrate 1m (ICE), fluorogenic
  • Note
    Research use only, not for human use.
  • Brief Description
    Caspase 1 Substrate 1m (ICE), fluorogenic; Ac-YEVD-AMC
  • Description
    Caspase 1 Substrate 1m (ICE), fluorogenic; Ac-YEVD-AMC
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GKI-1

    GKI-1 is a Greatwall (GWL) kinase inhibitor with an IC50 of 4.9 for hGWLFL and 2.5 μM for hGWL-KinDom. It exhibits stronger inhibition on ROCK1 with an IC50 of 11 μM and only weakly inhibits PKA.

  • TLQP-30

    Chronic intracerebroventricular (ICV) injection of a VGF peptide named TLQP-21 increased resting energy expenditure and temperature in mice. Furthermore, in mice fed a high-fat diet, the same peptide prevented the increase in body and white adipose tissue (WAT) weight as well as hormonal changes associated with a high-fat regimen.

  • Picrasidine I

    Picrasidine I has antiosteoclastogenic effect by inhibiting inflammation induced activation of MAPKs, ROS generation followed by suppressing the gene expression of c-Fos and NFATc1 in osteoclast precursors.